The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Tirzepatide vs Ozempic

Tirzepatide vs Ozempic: dual GLP-1/GIP agonist vs pure GLP-1 agonist. Direct head-to-head trials (SURPASS-2) show tirzepatide produces greater HbA1c reduction and weight loss than semaglutide 1 mg.

SURPASS-2 Direct Comparison

Tirzepatide 15 mg vs semaglutide 1 mg at 40 weeks: HbA1c reduction 2.46% vs 1.86%. Weight loss: 11.2 kg vs 5.7 kg. Tirzepatide showed statistically significant superiority on both primary endpoints.

Mechanism Difference

Ozempic (semaglutide): pure GLP-1 receptor agonism. Tirzepatide (Mounjaro): dual GLP-1/GIP agonism. The GIP component enhances insulin secretion in a glucose-dependent manner and improves insulin sensitivity in adipose tissue.

Brand Name Clarification

Mounjaro and Zepbound both contain tirzepatide. Ozempic and Wegovy both contain semaglutide. Mounjaro is approved for T2D; Zepbound for obesity. Ozempic for T2D; Wegovy for obesity.